RALEIGH, N.C., July 24, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company"), a development-stage pharmaceutical company, announced today that the Company received an additional notice of non-compliance on July 21, 2009 from the staff of the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff"). The Staff determined that the Company did not meet the terms of the extension granted to the Company in May 2009, which required the Company to demonstrate compliance with the $2.5 million stockholders' equity requirement of Listing Rule 5550(b). As a result, the Staff notified the Company that trading of the Company's common stock would be suspended at the opening of business on July 30, 2009, unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (the "Panel").
